10:22 AM EST, 01/07/2025 (MT Newswires) -- Recursion Pharmaceuticals ( RXRX ) received regulatory approvals for two drug trials.

The UK Medicines and Healthcare Products Regulatory Agency approved a phase 1 trial of REC-3565, a MALT1 inhibitor targeting B-cell cancers, the company said Tuesday in a statement.

The US Food and Drug Administration cleared a phase 1/2 trial of LSD1 inhibitor for small-cell lung cancer REC-4539, the company said.

Price: 7.74, Change: -0.21, Percent Change: -2.70